Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29974)	1/8/2000 4:47:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 32384

Henry, this is really interesting. So we have two groups, those that responded and those that improved but less than the responder measurement bogie. All are within a population which failed other treatments. It is easy to see why the FDA approved for all stages.

To: Henry Niman who wrote (29974)	1/8/2000 9:40:00 PM
From: Torben Noerup Nielsen	Read Replies (3) \| Respond to of 32384

Who is this Dr. Simon? He seems to have a fixation with statistics. Suppose I were a doctor and had a reasonably sized group of terminally ill patients. Somehow I come up with a concoction that I think might help them and I give it to all of them. Suppose that in a little while all of them recover. According to Dr. Simon, that doesn't mean anything since I didn't have a control group. That is, I should have divided the group in two, given half the concoction and the other a placebo and waited till the placebo group had died off before I would be allowed to conclude that my concoction did any good. Statistics should never be used as a substitute for common sense. Thanks, Torben